B.A, M.B.A, Founder & CEO, Hinge Bio, Inc.
Carin Mueller Rollins is Founder & CEO of Hinge Bio, Inc. She has been involved in the biotech field for nearly 25 years and has a unique mix of experience in venture capital, management consulting and equity research. Carin was previously co-founder of 5AM Ventures, an early-stage life science venture fund, where she specialized in company creation efforts and was founding Board Member of Marcadia (sold to Roche in 2011) and KaloBios (IPO in 2013). She also was an Investment Manager with Bay City Capital, an Associate in the pharmaceuticals practice of Booz Allen & Hamilton and an Equity Research Associate with the investment bank Robertson Stephens & Company. Carin holds a B.A. in Biology from Colgate University, where she served as a Trustee, and an MBA from the Stanford Graduate School of Business.
Hinge Bio is leveraging proprietary technology to make antibodies “flexible” so they can bind disease targets more efficiently with two (or more) hands cooperatively, enabling superior efficacy, safety and quality.